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Abstract Taxol (a trademarked product of Bristol-Myers
Squibb) is a complex isoprenoid natural product which has
displayed potent anticancer activity. Originally isolated from
the Pacific yew tree (Taxus brevifolia), Taxol has been mass-
produced through processes reliant on plant-derived biosyn-
thesis. Recently, there have been alternative efforts to recon-
stitute the biosynthetic process through technically convenient
microbial hosts, which offer unmatched growth kinetics and
engineering potential. Such an approach is made challenging
by the need to successfully introduce the significantly foreign
enzymatic steps responsible for eventual biosynthesis. Doing
so, however, offers the potential to engineer more efficient and
economical production processes and the opportunity to de-
sign and produce tailored analog compounds with enhanced
properties. This mini review will specifically focus on heter-
ologous biosynthesis as it applies to Taxol with an emphasis
on the challenges associated with introducing and reconstitut-
ing the downstream reaction steps needed for final bioactivity.
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Introduction
The term “complex natural products” has traditionally
been reserved for those compounds with both extensive
biosynthetic pathways and unique final molecular struc-
tures (Katz 1997). Examples include the polyketide com-
pound erythromycin A (antibiotic), the nonribosomal
peptide compound echinomycin (anticancer), and the iso-
prenoid compound Taxol (anticancer; Fig. 1). Each is
represented by a multi-step biosynthetic scheme which
includes coordinated enzymatic activity to produce the
final molecular structure. Such complexity poses chal-
lenges during initial attempts to elucidate the underlying
biosynthetic pathways responsible for compound formation
and during early compound molecular characterization
efforts. Challenges are also encountered during attempts
at pathway engineering and chemical or biological synthe-
sis for the purpose of compound overproduction. Yet, de-
spite this complexity and the resulting challenges, basic
and applied research emerged and persists because of the
medicinal value associated with such natural products, a
property intrinsically associated with the same molecular
complexity that complicates characterization and produc-
tion efforts.
Among the groups of natural products capable of being
classified as complex are the isoprenoids. This is a particu-
larly large classification with tens of thousands of examples
having been identified including those, like Taxol, which
have resulted in blockbuster drug therapies (McGarvey and
Croteau 1995; Sacchettini and Poulter 1997). Focusing on
the Taxol compound, the final product meets the criteria for
complexity as a result of a putative 19 step biosynthetic
pathway and a final molecular architecture featuring 11
chiral centers (Croteau et al. 2006) (Fig. 2). The biosynthetic
process begins with the intracellular supply of universal
isoprenoid substrates isopentenyl diphosphate (IPP) and
dimethylallyl diphosphate (DMAPP) followed by polyiso-
prene formation of a geranylgeranyl diphosphate (GGPP)
molecule which is cyclized by the first dedicated enzyme
(taxadiene synthase) of the biosynthetic pathway (Wildung
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and Croteau 1996). In the larger context of complex natural
product biosynthesis, an early stage intermediate, such as
taxadiene, provides a platform for tailoring reactions to
produce the final compound. These include reduction,
hydroxylation, acetylation, glycosylation, methylation,
and other modifications to confer the specific molecular
architecture needed for bioactivity (Olano et al. 2010;
Walsh et al. 2001). In the case of Taxol, there are
reactions dedicated to hydroxylations, oxidation, epoxida-
tion, acetylations, benzoylations, and an amino acid mod-
ification and addition. Notably, there is the utilization of
several cytochrome P450 hydroxylase enzymes within
the Taxol tailoring reactions (Jennewein et al. 2004b;
Kaspera and Croteau 2006).
As mentioned, the diverse molecular architectures asso-
ciated with complex natural products like Taxol are directly
responsible for final natural product biological activity. The
role of this activity in nature is speculated to be defensive.
Foreign organism invasion, cellular damage, and resource
limitation have all been linked to natural product formation
(Ajikumar et al. 2008; Maplestone et al. 1992). Man-made
production efforts are then aimed at harnessing biosynthesis
for the purpose of redirecting the medicinal properties of
natural products towards human disease, an approach that
has been successful and has led to numerous antibiotics,
anticancer agents, and other medicines currently available
(Newman and Cragg 2007).
However, the therapeutic potential of natural products is
often tempered by the non-ideal growth properties of the
original hosts responsible for compound formation. Alter-
native attempts to chemically synthesize the compound
must contend with the significant challenges in mimicking
natural chemistry, leaving cell-based biosynthesis as the
only economical route to production. The slow-growing or
fastidious nature of most original cellular producers acts as a
final degree of complexity associated with medicinally rel-
evant natural products. Many natural product producers are
soil- or marine-dwelling microorganisms. In the case of
Taxol and other isoprenoids, plants are a significant source
of compounds. Each of these native producers is fastidious
in nature, slow-growing, difficult to implement into scale-
able production processes, or a combination of these traits.
Furthermore, many other natural product producers (>99 %)
are considered unculturable (Amann et al. 1995), supporting
the viewpoint that the potential of encoded natural prod-
uct pathways is greatly complicated by the native host
producers.
Interestingly, the most technically convenient microbial
hosts like Escherichia coli and Saccharomyces cerevisiae,
which have been used widely across the biotech industry,
have little propensity for natural product biosynthesis. In the
context of heterologous biosynthesis, this lack of production
has both advantages and disadvantages (Zhang et al. 2011a).
First, while there is little question that successful
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reconstitution of a complex, therapeutically relevant natural
product pathway in a convenient microbial heterologous
host would aid basic and applied studies, the lack of pre-
requisite metabolic support increases the challenge of suc-
cessful reconstitution. For example, a separate metabolic
engineering strategy may be required to introduce or en-
hance substrates required by downstream biosynthetic
enzymes. Alternatively, the lack of native natural product
pathways may (1) simplify efforts to regulate the introduced
pathway; (2) require less metabolic engineering to eliminate
“cross talk” with existing natural product pathways; and (3)
result in a cleaner purification process without contaminating
native products.
Over the last 10 years, several studies have focused on the
production of complex plant-derived isoprenoids through E.
coli and S. cerevisiae. This review will place particular em-
phasis on the Taxol biosynthetic pathway and the tailoring
reactions needed to generate final bioactivity. Considering that
the current state-of-the-art is the production of early stage
Taxol intermediates through heterologous hosts, this discus-
sion will summarize success to date and the steps needed to
realize and capitalize upon full pathway reconstitution.
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Fig. 2 The downstream Taxol biosynthetic pathway. Those enzymes
shown have demonstrated activity either biochemically or biosyntheti-
cally towards the indicated substrate and include geranylgeranyl di-
phosphate synthase (GGPPS; Hefner et al. 1998), taxadiene synthase
(Wildung and Croteau 1996; Koepp et al. 1995; Huang et al. 2001),
taxadiene 5α-hydroxylase (Jennewein et al. 2004a), taxane 2α-O-
benzoyltransferase (TBT; Walker and Croteau 2000b), 10-deacetylbaccatin
III-10-O-acetyl transferase (DBAT; Walker and Croteau 2000a), baccatin
III:3-amino-3-phenylpropanoyltransferase (BAPT; Walker et al. 2002a),
and phenylalanine aminomutase (PAM; Walker et al. 2004). Other enzymes
(taxadien-5α-ol-O-acetyl transferase, taxoid 10β-hydroxylase, taxoid 2α-
hydroxylase, taxoid 9α-hydroxylase, taxane 13α-hydroxylase, taxoid 7β-
hydroxylase, and 3′-N-debenzoyl-2′-deoxytaxol N-benzyoyltransferase)
have been identified and/or characterized but not conclusively assigned a
location in the overall pathway order (Walker et al. 2000; Schoendorf et al.
2001; Chau and Croteau 2004; Croteau et al. 2006; Jennewein et al. 2001;
Chau et al. 2004; Walker et al. 2002b). Still other enzymes (taxoid 1β-
hydroxylase, taxoid 9-keto-oxidase, β-phenylalanoyl-CoA ligase, taxoid
2′-hydroxylase, and those involved with oxetane ring formation) have not
been identified. IDI isopentenyl diphosphate isomerase, CPR cytochrome
P450 reductase
Appl Microbiol Biotechnol (2012) 94:841–849 843
Heterologous biosynthetic logic: upstream
and downstream components
Being confined to a cellular environment, heterologous pro-
duction attempts begin with the basic substrates, cofactors,
and other metabolites needed to support biosynthesis.
Isoprenoid biosynthesis substrates can be derived from one
of two pathways, and both have been used in previous
heterologous settings. The mevalonate (MVA) pathway, na-
tive to S. cerevisiae, begins with acetyl-CoA (Bloch 1992;
Miziorko 2011); whereas, the alternative methylerythritol
phosphate (MEP) pathway, native to E. coli, begins with a
molecule each of pyruvate and glyceraldehyde 3-phosphate
(Grawert et al. 2011; Rohmer 1999). These substrates can be
linked to primary metabolic pathways that must be re-routed
when triggered (either natively or heterologously) for iso-
prenoid biosynthesis. The formation of the IPP and DMAPP
by the MVA or MEP pathways is considered the upstream
portion of overall biosynthesis. In the context of heterolo-
gous metabolic engineering, in which the objective is to
establish production of a non-native isoprenoid compound,
the substrate provision pathways must minimally be able to
support even the smallest level of eventual final product
formation. Whereas, in pathway metabolic engineering, the
goal is to maximize specific productivities and the upstream
pathway must then be optimized to support final compound
overproduction.
The downstream portion of isoprenoid biosynthesis are
those reactions dedicated to polyisoprene formation, tem-
plate compound cyclization, and template compound tailor-
ing. Unlike the upstream pathway, there is generally no
direct link to primary metabolism and the introduced
metabolism is foreign. As such, there are a series of
precautions to be taken to aid the process of functional
gene expression. These challenges derive primarily be-
cause of the cell-specific differences between native and
heterologous hosts. As an example, the genetic, physio-
logical, and structural differences between a plant cell and
an E. coli cell impact everything from gene expression
templates and parameters to physical enzyme location
post-expression.
With regards to Taxol, both S. cerevisiae and E. coli have
been used to generate early stage intermediates in the down-
stream pathway (Ajikumar et al. 2010; Dejong et al. 2006;
Engels et al. 2008; Huang et al. 2001). Both hosts are strong
candidates for heterologous biosynthesis as a function of
their rapid growth rates (compared to plant cells) and range
of molecular biology tools to facilitate and optimize meta-
bolic engineering efforts. Given the fact that the entire
pathway has yet to be incorporated into either host, it is
unknown which will serve the purpose of complete Taxol
heterologous biosynthesis. The choice may then be decided
by individual researcher preference or biased by host- or
pathway-specific features. Over the last 10 years, the emer-
gence of facilitating technical developments for hosts like E.
coli and S. cerevisiae have continually fueled and allowed
increasing attempts at heterologous natural product biosyn-
thesis with great success. For example, gene synthesis and
chromosomal engineering methodology helped expedite the
heterologous transfer and reconstitution process for artemi-
sinin (an antimalarial compound) and Taxol intermediate
production (Ajikumar et al. 2010; Martin et al. 2003; Ro et
al. 2006). The downstream pathways for complex isopren-
oid compounds typically feature several steps catalyzed by
plant cytochrome P450 enzymes and a partner reductase
(Croteau et al. 2006; Jennewein et al. 2005; Kaspera and
Croteau 2006). Besides the usual challenges in establishing
functional enzymatic activity in a heterologous host, these
enzymes are membrane bound and may benefit from a
heterologous cellular structure similar to that found in
plants. From this perspective, S. cerevisiae would be at an
advantage relative to E. coli. However, similar to the advan-
ces that have aided biosynthetic efforts to this stage, should
new technology allow for efficient and functional expres-
sion of a series of such complicated enzymes within either
E. coli or S. cerevisiae, both hosts would then be viable
options for heterologous biosynthesis.
Challenges and options associated with the heterologous
implementation of the Taxol downstream biosynthetic
pathway
The challenges facing heterologous Taxol formation
through microbial hosts mirror those for other complex
natural products. Namely, genetic material must be available
for transfer, successful gene expression and enzymatic ac-
tivity must be accomplished in the new host, and sensitive
analytical capabilities must be available to characterize and
quantify compound formation. The process is aided by a
working knowledge of the biochemical steps in product
formation and experimental options to address the many
issues that can arise during heterologous production
attempts. In this regard, current work took advantage of
previously established results in Taxol pathway analysis
and emerging technology available with microbial hosts to
assist reconstitution efforts.
The first requirement in establishing heterologous bio-
synthesis is to have access to the native biosynthetic genes
responsible for product formation. Given the medicinal val-
ue of natural products like Taxol, significant investment has
been made to elucidate the responsible biosynthetic path-
way. On this front, Rodney Croteau’s group at Washington
State University made significant advances in identifying
genes of the Taxol pathway and testing expression in heter-
ologous hosts.
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Early efforts to identify the exact biosynthetic steps to-
wards Taxol’s production were published in the mid to late
1990s (Hefner et al. 1998, 1996; Hezari et al. 1995; Koepp
et al. 1995; Walker et al. 1999; Wildung and Croteau 1996).
This work identified the geranylgeranyl diphosphate syn-
thase, taxadiene synthase, cytochrome P450 hydroxylase,
and acetyltransferase needed to make the hypothesized first
three dedicated intermediates of the Taxol pathway. Four of
these six initial isolation studies were conducted with native
Taxus plant sources providing the enzymes of interest. A
concerted attempt was then made to generate cDNA librar-
ies from Taxus cell cultures and to begin identifying and
confirming subsequent pathway genes (Chau and Croteau
2004; Chau et al. 2004; Huang et al. 2001; Jennewein et al.
2001, 2004b; Long and Croteau 2005; Schoendorf et al.
2001; Walker and Croteau 2000a, b; Walker et al. 2002a,
b, 2000, 2004).
These results were commendable from several view-
points. First, the work helped establish a hypothetical bio-
synthetic path to the final Taxol molecule (Fig. 2), while
simultaneously providing the genetic blueprint to consider
reconstructing the downstream pathway in heterologous
hosts. Both E. coli and S. cerevisiae were used throughout
studies to overproduce and characterize pathway enzymes.
On occasion, insect (Spodoptera frugiperda 9) hosts were
used as alternatives to achieve higher expression levels or
when problems emerged with the more convenient heterol-
ogous hosts (Chau et al. 2004; Jennewein et al. 2004a, 2005,
2001). In each of these examples, a pathway P450 or P450
reductase was also tested for expression in S. cerevisiae.
Generally, Croteau’s group favored S. cerevisiae for P450
heterologous expression (Jennewein et al. 2003, 2004a;
Schoendorf et al. 2001; Chau et al. 2004), most likely owing
to the similarities to the native plant host. E. coli was
prominently featured as an expression host with other path-
way genes (Huang et al. 1998; Walker and Croteau 2000a,
b; Walker et al. 2002a, b, 2000, 2004). Each of these
heterologous expression attempts set the stage for heterolo-
gous biosynthetic production.
Not surprisingly, Croteau’s group took the lead in
attempting to produce intermediates from the Taxol pathway
through technically convenient heterologous hosts. The first
attempts used E. coli to express the taxadiene synthase gene
for the purpose of producing the first Taxol pathway inter-
mediate (Huang et al. 2001). Prior to this success, E. coli
taxadiene synthase expression and activity was systemati-
cally evaluated across gene expression parameters and hosts
(Huang et al. 1998; Wildung and Croteau 1996; Williams et
al. 2000). The T7 promoter expression system was featured
in these attempts; however, variations were made according
to the strains tested for expression (including K vs. B line-
ages). Expression was also optimized to avoid inclusion
body formation and/or inactivity by the use of fusion
proteins and the removal of an N-terminal signaling peptide
which was specific for subcellular membranes in plant cells.
These approaches, coupled with induced expression at re-
duced temperatures (20–25°C), resulted in much improved
enzyme levels and activity. However, before heterologous
taxadiene production was achieved, separate genes encod-
ing for MEP pathway steps or an Erwinia herbicola gera-
nylgeranyl diphosphate synthase were required to allow
final taxadiene titers of 1.3 mg/L.
An ambitious attempt at S. cerevisiae heterologous pro-
duction was made through the coordinated expression of the
first five hypothesized steps in Taxol formation (from IPP
and DMAPP). The geranylgeranyl diphosphate synthase
and taxadiene synthase were again truncated to remove
plant-specific signal sequences; whereas, constructs for the
expected next three steps (taxadiene 5α-hydroxylase,
taxadien-5α-ol-O-acetyl transferase, and taxoid 10β-
hydroxylase responsible for taxadien-5α-ol, taxadien-5α-
yl-acetate, and taxadien-5α-acetoxy-10β-ol, respectively)
were used based upon successful previous expression
attempts in either E. coli or S. cerevisiae (Jennewein et al.
2004a, 2001; Schoendorf et al. 2001). Taxadiene titers were
reported at 1.0 mg/L though only trace amounts of the
second intermediate (taxadien-5α-ol) were observed
(Dejong et al. 2006); taxadien-5α-yl-acetate and taxadien-
5α-acetoxy-10β-ol were not conclusively identified, em-
phasizing the uncertainty with the overall pathway past
taxadien-5α-ol formation (Fig. 2). A later effort by Stefan
Jennewein’s group to optimize the heterologous production
of taxadiene from S. cerevisiae was notable for the applica-
tion of metabolic engineering to improve biosynthetic sub-
strate availability, the use of a codon-optimized taxadiene
synthase gene, and final taxadiene levels of 8.7 mg/L
(Engels et al. 2008).
However, in either case, whether for biochemical charac-
terization or heterologous production, ensuring successful
gene expression in foreign hosts is not trivial. The body of
work presented above served as a valuable basis for recent
attempts at heterologous Taxol (or other isoprenoid) produc-
tion attempts. The most recent efforts derive both from the
focused work on Taxol biosynthesis and the more general
advances in metabolic engineering and gene expression that
have occurred over the last 10 years. A combination of
metabolic engineering and optimized gene expression led
to improved (~300 mg/L) production of taxadiene from E.
coli (Ajikumar et al. 2010). Here, metabolic engineering
was used to balance the flow of carbon between upstream
and downstream pathways as a way to optimize final titers.
However, when establishing the downstream pathway with-
in a foreign host, great care must be taken to correctly
design the newly introduced gene(s) for successful expres-
sion. Croteau’s group recognized this by removing plastidial
regions from the 5′ regions of genes to be expressed in E.
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coli. In addition to this step, the approach by Ajikumar et al.
featured gene synthesis, gene dosage levels (chromosomal
and varying copy number plasmid expression), promoter var-
iation (T7, T5, and trc), and process temperature to influence
and optimize final enzyme function in the context of heterol-
ogous biosynthesis. The combination ofmetabolic engineering
and gene expression technology, together with the prior
knowledge provided by the efforts of the Croteau group,
allowed high level taxadiene formation from E. coli (Table 1).
The engineering approaches mentioned above were first
used to maximize E. coli taxadiene formation. However,
subsequent P450 steps were made more complicated for
several reasons. First, these enzymes are membrane associated
with the endoplasmic reticulum of native hosts (Bernhardt
2006). Approximating this membrane localization in E. coli
will clearly be challenging. However, taking the lead from
numerous groups that have focused on E. coli gene expression
of mammalian and plant P450 enzymes (Barnes 1996; Barnes
et al. 1991; Chang et al. 2007; Jenkins et al. 1998; Leonard et
al. 2006; Pritchard et al. 2006; Yun et al. 2006), functional
expression of the first Taxol pathway P450 was accomplished
(Ajikumar et al. 2010). Doing so required truncation of the
native transmembrane region (with three different truncation
lengths tested) and further modification of the N-terminal
portion of the enzyme to include an eight amino acid mem-
brane anchor peptide sequence (MALLLAVF) which has
proven functional in E. coli (Barnes et al. 1991). Furthermore,
as in the case of the taxadiene synthase, the P450 gene was
synthesized to eliminate any codon bias (this same step
was also taken for the accompanying P450 reductase),
and reduced temperature induction conditions and other
process parameters were modified so as to maximize
eventual production (Table 1).
An additional complication of the Taxol P450 enzymes is
the need for a dedicated reductase (CPR) partner. This can
be mitigated by the native capabilities to complement re-
ductase activity when using S. cerevisiae, but the same level
of convenience may not be provided with E. coli (Barnes et
al. 1991; Jenkins and Waterman 1998; Jennewein et al.
2005; Oeda et al. 1985). Again thanks to work by Rodney
Croteau’s group, a reductase has been isolated from Taxus
cuspidata (Jennewein et al. 2005). The reductase was also
modified by N-terminal transmembrane region removal pri-
or to covalently coupling the reductase to the P450 through
a linker peptide (Ajikumar et al. 2010), as a means to co-
localize the enzyme pair and to mimic highly active fusion
P450-reductase examples found in nature (Fisher et al.
1992; Fisher et al. 1996; Leonard et al. 2006; Munro et al.
2002; Narhi and Fulco 1982). A series of codon-optimized,
truncated fusion P450-reductase pairs were then tested for
coupling to the previously optimized metabolism for E. coli
taxadiene formation with titers of taxadien-5α-ol reaching
58 mg/L. Productions efforts also revealed, however, the
formation of an unwanted hydroxylated isomer, which
suggests inefficiencies in expression design and/or protein
activity. This unwanted side product presents a current
challenge in optimizing production through E. coli.
However, given successful previous efforts to apply protein
engineering to P450 enzymes (Grogan 2011; Urlacher and
Girhard 2011), there is reason to believe similar strategies
could be applied for the purpose of improving the specific
productivity of taxadien-5α-ol using the E. coli system.
Table 1 Genetic, protein, and process modifications to facilitate high titer production of taxadiene and taxadien-5α-ol from E. coli
Gene synthesis N-terminal
peptide removal
N-terminal
peptide addition
Linker region to
produce fusion protein
Reduced temperature
culture conditions
Bioreactor
production
TXS and GGPPS ✓ ✓ ✓ ✓
P450 and CPR ✓ ✓ ✓ (P450 only) ✓ ✓ ✓
TXS taxadiene synthase, GGPPS geranylgeranyl diphosphate synthase, P450 cytochrome P450, CPR cytochrome P450 reductase
Table 2 Representative complex natural products heterologously produced through E. coli
Compound Total biosynthetic
stepsa
Heterologous product
(biosynthetic number of steps)
Number of P450
enzymes introduced
Final titer
(mg/L)
References
Erythromycin Ab
(polyketide)
20 Erythromycin A (20) 2 4 (Zhang et al. 2011b, 2010)
Echinomycinb
(nonribosomal peptide)
14 Echinomycin (14) 1 0.3 (Watanabe et al. 2006)
Taxol (isoprenoid) 19 Taxadien-5α-ol (2) 1 58 (Ajikumar et al. 2010)
a Not including those steps required to provide the starting substrates for compound biosynthesis. Number for Taxol begins from geranylgeranyl
diphosphate and is considered putative as not all steps have been conclusively identified
b Both systems include modular enzymes responsible for catalyzing multiple reaction steps. For simplification, these enzymes have been counted as
one step such that the total number of steps is equal to the number of heterologous enzymes required
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In summary, the last 15 years have seen increasing efforts
to heterologously produce complex isoprenoid compounds
using hosts such as E. coli. In the case of the Taxol system,
the combination of an emerging biosynthetic pathway and
improvements in the expression technology available to
transfer this pathway into alternative hosts has led to
successful production of the first two dedicated pathway
intermediates. The question now turns to complete pathway
implementation and optimization for sufficient heterologous
production and which cellular platform will eventually
better serve this purpose.
Complete biosynthesis: a combination of heterologous
and pathway metabolic engineering
The eventual goal of heterologous biosynthesis is to produce
the original natural product and designed analogs at titers
sufficient to allow mass distribution. This can only be done
with successful metabolic engineering, both to establish
initial production and then to maximize the flow of carbon
through upstream and downstream biosynthetic compo-
nents. Initial reconstitution has been accomplished for com-
plex polyketide and nonribosomal peptide natural products,
with both examples requiring multiple tailoring reactions to
complete biosynthesis (Table 2). In these cases, pathway
metabolic engineering has not yet allowed overproduction.
In other words, though each final natural product has been
impressively generated through a surrogate host, current
titers are too low to present a viable production route.
Interestingly, pathway metabolic engineering has been
used successfully to generate substantial titers of heterolo-
gous isoprenoid compounds (Ajikumar et al. 2010; Chang et
al. 2007; Ro et al. 2006). However, these compounds have
only been intermediates in the overall downstream path-
ways. In the case of the Taxol intermediate taxadiene, grams
per liter titers have been accomplished through careful bal-
ancing of the upstream and downstream biosynthetic path-
ways coupled to small-scale bioreactor systems (Ajikumar
et al. 2010). The artemisinin intermediate amorphadiene has
also been produced at grams per liter levels through the
application of metabolic and process engineering (Martin
et al. 2003; Tsuruta et al. 2009). Production of the remaining
downstream intermediates for both compounds requires the
introduction of P450 and other tailoring enzymes and has
not reached the same concentration levels associated with
taxadiene and amorphadiene (although it should be noted
that the artemisinin intermediate artemisinic acid (Ro et al.
2006) could be produced and linked to a semi-synthetic
strategy to generate the full compound).
This scenario points to the challenges in establishing
complete and sufficient biosynthesis, especially when
unique biosynthetic steps are introduced to a significantly
different host system. Furthermore, in the case of Taxol,
several steps in the overall pathway have not been conclu-
sively identified or confirmed. As such, research must con-
tinue to be directed at strategies to discover and characterize
missing pathway enzymes. However, if the heterologous
route is ever to become viable, these challenges must be
overcome. In addition, high titer production must also be
reproducible, non-toxic to the new host (allowing high-cell-
density bioprocesses), and adjustable for the production of
rationally designed analogs. In the case of Taxol, heterolo-
gous biosynthesis would allow several opportunities. First,
an E. coli or S. cerevisiae production platform (either for the
final compound or an intermediate capable of being con-
verted to the final compound via semi-synthesis) would
offer a potentially faster and more economical route to the
current Taxol product. Second, reconstitution offers the
opportunity to directly alter biosynthesis for the purpose of
producing new analogs with improved potency and a
broader therapeutic spectrum (Long et al. 1998; Woo et al.
1994; Young et al. 1992; Zhang et al. 2005) or for the
purpose of improving post-administration in vivo bioavail-
ability (a problem that has plagued the hydrophobic Taxol
molecule (Hennenfent and Govindan 2006)).
This is the vision of heterologous biosynthesis. It will be
interesting to see where the field stands in another 10 years.
Now, with the advantage of hindsight, it is clear the
approach can be used for the production of complex natural
compounds, most notably, polyketides and nonribosomal
peptides. Over the next decade, the continued application
of metabolic engineering concepts will decide the range of
compounds to be completely biosynthesized and the pro-
duction titers that would support eventual process viability.
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